We are live on ! Find out more
GLUE icon

Monte Rosa Therapeutics
GLUE

81 hedge funds and large institutions have $264M invested in Monte Rosa Therapeutics in 2024 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 41 increasing their positions, 11 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

442% more call options, than puts

Call options by funds: $895K | Put options by funds: $165K

273% more repeat investments, than reductions

Existing positions increased: 41 | Existing positions reduced: 11

100% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 7

54% more capital invested

Capital invested by funds: $171M → $264M (+$92.2M)

9% more funds holding

Funds holding: 74 → 81 (+7)

6.12% more ownership

Funds ownership: 74.96% → 81.07% (+6.1%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
81
Holders Change
+7
Holders Change %
+9.46%
% of All Funds
1.16%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
14
Increased
41
Reduced
11
Closed
7
Calls
$895K
Puts
$165K
Net Calls
+$730K
Net Calls Change
+$445K

Top Buyers

Rank Fund Capital Flow
1
ACA
Avoro Capital Advisors
New York
+$6.34M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$3.15M
3
BlackRock
BlackRock
New York
+$2.73M
4
PL
Parkwood LLC
Ohio
+$2.15M
5
IC
Ikarian Capital
Texas
+$1.57M

Top Sellers

Rank Fund Capital Flow
1
SFM
Sphera Funds Management
Israel
-$1.3M
2
CC
Casdin Capital
New York
-$883K
3
Jane Street
Jane Street
New York
-$257K
4
SP
Sarasin & Partners
United Kingdom
-$243K
5
Renaissance Technologies
Renaissance Technologies
New York
-$182K
Name Holding Trade Value Shares
Change 		Change in
Stake
Dimensional Fund Advisors
26
Dimensional Fund Advisors
Texas
$738K -$73.1K -14,485 -9%
Morgan Stanley
27
Morgan Stanley
New York
$664K +$288K +56,990 +83%
SFM
28
Sphera Funds Management
Israel
$626K -$1.3M -256,897 -69%
Manulife (Manufacturers Life Insurance)
29
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$625K +$76.6K +15,168 +15%
Acadian Asset Management
30
Acadian Asset Management
Massachusetts
$586K +$62K +12,278 +12%
N
31
Nuveen
North Carolina
$545K +$69.3K +13,739 +15%
BFM
32
Boothbay Fund Management
New York
$484K +$461K +91,292 New
CC
33
Casdin Capital
New York
$456K -$883K -175,000 -67%
Bank of America
34
Bank of America
North Carolina
$389K +$24.8K +4,916 +7%
American Century Companies
35
American Century Companies
Missouri
$320K +$55.3K +10,955 +22%
Barclays
36
Barclays
United Kingdom
$289K +$220K +43,499 +395%
RhumbLine Advisers
37
RhumbLine Advisers
Massachusetts
$278K +$22.9K +4,543 +9%
LCAM
38
Long Corridor Asset Management
Hong Kong
$212K – – –
HF
39
HRT Financial
New York
$206K +$196K +38,911 New
State of Wisconsin Investment Board
40
State of Wisconsin Investment Board
Wisconsin
$192K -$46.4K -9,200 -20%
AllianceBernstein
41
AllianceBernstein
Tennessee
$186K +$11.9K +2,360 +7%
EC
42
EntryPoint Capital
New York
$176K +$168K +33,219 New
Millennium Management
43
Millennium Management
New York
$162K +$48.9K +9,693 +46%
Citigroup
44
Citigroup
New York
$160K +$104K +20,565 +216%
ETC
45
Exchange Traded Concepts
Oklahoma
$158K -$29.7K -5,888 -16%
UBS Group
46
UBS Group
Switzerland
$134K +$10.3K +2,039 +9%
BCM
47
Bridgeway Capital Management
Texas
$133K +$126K +25,000 New
MIM
48
MetLife Investment Management
New Jersey
$132K +$125K +24,855 New
UBS AM
49
UBS AM
Illinois
$128K +$42.9K +8,500 +54%
Mirae Asset Global ETFs Holdings
50
Mirae Asset Global ETFs Holdings
Hong Kong
$120K +$32K +6,347 +39%
1
2
3 4

GLUE Hedge Fund Activity: Q3 2024 in Review

81 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Monte Rosa Therapeutics (GLUE) for Q3 2024, worth a combined $264M — up 54% from $171M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new GLUE positions and 7 closed out — a net gain of 7 holders — while 41 added to existing stakes and 11 trimmed.

The largest buyer was Avoro Capital Advisors, adding an estimated $6.34M. The largest seller was Sphera Funds Management, cutting an estimated $1.3M.

  • 81 institutional investors held Monte Rosa Therapeutics (GLUE) as of Q3 2024, up from 74 in Q2 2024.
  • Funds reported $264M of Monte Rosa Therapeutics stock for Q3 2024, up 54% quarter-over-quarter.
  • 14 funds opened new Monte Rosa Therapeutics positions in Q3 2024 and 7 closed out, a net change of +7 holders.
  • The largest Monte Rosa Therapeutics buyer in Q3 2024 was Avoro Capital Advisors, an estimated $6.34M added.
  • The largest Monte Rosa Therapeutics seller in Q3 2024 was Sphera Funds Management, an estimated $1.3M sold.

Based on aggregated 13F filings for Q3 2024.